இத்தாலிய தேவதூதர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இத்தாலிய தேவதூதர்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இத்தாலிய தேவதூதர்கள் Today - Breaking & Trending Today

PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate PEP-010


as well as a €1 million loan from Bpifrance
PARIS, July 19, 2021 /PRNewswire/  
PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension of its Series A financing round, bringing the total raised in this round to €5.4 million ($6.4 million). This new funding comprises €1.6 million in equity from Anaxago, i&i Prague and BADGE as well as a €1 million loan from Bpifrance.
This increased financial support highlights the potential of PEP-010, as well as PEP-Therapy s Cell Penetrating & Interfering Peptide (CP&IP) technology platform, which was first developed at Sorbonne University and Institut Curie. ....

Czech Republic , France General , Laboratoires Fournier , Bernard Majoie , Antoine Prestat , Gustave Roussy , Sylvie Berrebi , Institut Curie , Gaston Vasseur , Seed Fund , Sorbonne University , Fournier Majoie Foundation For Innovation , Bpifrance This , Cell Penetrating , Interfering Peptide , Investment Manager , Fonds Unique Interminist , Interfering Peptides , Italian Angels , Magna Capital Partners , Business Angels Des Grandes Ecoles , Seventure Partners , Founding Chairman , Fournier Majoie Foundation , Anaxago Venture Capital , Venture Capital ,

Big Money for Gene Editing, Engineering, Structure-Based Drug Design, and Data Management


April 29, 2021
April 29, 2021 | Illumina joins the Gates Foundation in a global pathogen genomics initiative, new money for immune profiling, and Benchling nets $200M for their cloud platform.
 
$375M: Fund for Growth-Stage Medtech, Digital Health 
Endeavour Vision has closed Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices, and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies 21 of which have exited via an acquisition or IPO. The fund has already supported seven compani ....

New Zealand General , New Zealand , Al Iskandariyah , Rhode Island , United States , World Health Organization , Al Qahirah , San Diego , Relievant Medsystems , Carll Gordon , Anne Wojcicki , Behzad Aghazadeh , Rory Mcilroy , Elad Gil , Andreessen Horowitz , Jennifer Doudna , Medable Inc , Kaia Health , Us Centers For Disease , Scribe Therapeutics Inc , Biomedical Research Excellence , Mental Health , Africa Pathogen Genomics Initiative , Fidelity Management Research Company , Melinda Gates Foundation , Deerfield Management Company ,